ONTX insider filings

Onconova Therapeutics, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2024-03-15. Screen ONTX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ONTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Onconova Therapeutics, Inc.

FiledFormInsiderReported transactionsSource
2024-03-154Guerin Mark Patrick — CFO AND COOOption exercise (M): 8,666 · Tax withholding (F): 2,591 @ $0.90 · Option exercise (M): 8,666 (derivative) @ $0EDGAR
2024-03-154Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, DirectorOption exercise (M): 23,111 · Tax withholding (F): 8,727 @ $0.90 · Option exercise (M): 23,111 (derivative) @ $0EDGAR
2024-02-094Guerin Mark Patrick — CFO AND COOOption exercise (M): 6,900 · Tax withholding (F): 2,443 @ $0.67 · Option exercise (M): 6,900 (derivative) @ $0EDGAR
2024-02-094Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, DirectorOption exercise (M): 21,320 · Tax withholding (F): 9,212 @ $0.67 · Option exercise (M): 21,320 (derivative) @ $0EDGAR
2023-10-274Moyo Victor M — CHIEF MEDICAL OFFICERGrant/award (A): 125,000 (derivative) @ $0EDGAR
2023-08-144Shoemaker Mary Teresa — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2023-08-144STOVER JACK E — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2023-08-144Atadja Peter — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2023-08-144Clarke Trafford — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2023-08-144MEHTA VIREN — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2023-08-144GROOPMAN JEROME — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2023-08-144MARINO JAMES J — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2023-08-044Guerin Mark Patrick — CFO AND COOOption exercise (M): 4,750 · Tax withholding (F): 1,422 @ $1.02 · Option exercise (M): 4,750 (derivative) @ $0EDGAR
2023-08-044Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, DirectorOption exercise (M): 12,567 · Tax withholding (F): 4,744 @ $1.01 · Option exercise (M): 12,567 (derivative) @ $0EDGAR
2023-06-134Guerin Mark Patrick — CFO AND COOOption exercise (M): 5,500 · Tax withholding (F): 1,575 @ $1.14 · Option exercise (M): 5,500 (derivative) @ $0EDGAR
2023-03-144Guerin Mark Patrick — CFO AND COOGrant/award (A): 79,000 (derivative) @ $0 · Grant/award (A): 26,000 (derivative) @ $0EDGAR
2023-03-144Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, DirectorGrant/award (A): 207,000 (derivative) @ $0 · Grant/award (A): 69,333 (derivative) @ $0EDGAR
2023-03-144Gelder Mark S. MD — CHIEF MEDICAL OFFICERGrant/award (A): 62,000 (derivative) @ $0 · Grant/award (A): 20,667 (derivative) @ $0EDGAR
2023-02-084Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, DirectorOption exercise (M): 21,320 · Tax withholding (F): 6,977 @ $1.36 · Option exercise (M): 21,320 (derivative) @ $0EDGAR
2023-02-084Gelder Mark S. MD — CHIEF MEDICAL OFFICEROption exercise (M): 5,833 · Tax withholding (F): 1,242 @ $1.36 · Option exercise (M): 5,833 (derivative) @ $0EDGAR
2023-02-084Guerin Mark Patrick — CFO AND COOOption exercise (M): 6,900 · Tax withholding (F): 1,785 @ $1.36 · Option exercise (M): 6,900 (derivative) @ $0EDGAR
2022-12-194Clarke Trafford — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2022-12-194Atadja Peter — DirectorGrant/award (A): 100,000 (derivative) @ $0EDGAR
2022-08-194STOVER JACK E — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2022-08-194MARINO JAMES J — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2022-08-194MEHTA VIREN — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2022-08-194Shoemaker Mary Teresa — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2022-08-194GROOPMAN JEROME — DirectorGrant/award (A): 66,468 (derivative) @ $0EDGAR
2022-08-044Guerin Mark Patrick — CFO AND COOOption exercise (M): 4,750 · Tax withholding (F): 1,355 @ $1.32 · Option exercise (M): 4,750 (derivative) @ $0EDGAR
2022-08-044Gelder Mark S. MD — CHIEF MEDICAL OFFICEROption exercise (M): 4,650 · Tax withholding (F): 1,135 @ $1.32 · Option exercise (M): 4,650 (derivative) @ $0EDGAR
2022-08-044Fruchtman Steven M — PRESIDENT, CHIEF EXECUTIVE OFF, DirectorOption exercise (M): 12,566 · Tax withholding (F): 4,562 @ $1.32 · Option exercise (M): 12,566 (derivative) @ $0EDGAR
2022-06-134Guerin Mark Patrick — COO and CFOGrant/award (A): 50,250 (derivative) @ $0 · Grant/award (A): 16,500 (derivative) @ $0EDGAR
2022-02-094Gelder Mark S. MD — Chief Medical OfficerGrant/award (A): 51,750 (derivative) @ $0 · Grant/award (A): 17,500 (derivative) @ $0EDGAR
2022-02-094Fruchtman Steven M — President, Chief Executive Off, DirectorGrant/award (A): 191,880 (derivative) @ $0 · Grant/award (A): 63,960 (derivative) @ $0EDGAR
2022-02-094OLER ABRAHAM N. — SVP Corp Dev & Gen CounselGrant/award (A): 54,050 (derivative) @ $0 · Grant/award (A): 17,633 (derivative) @ $0EDGAR
2022-02-094Guerin Mark Patrick — Chief Financial OfficerGrant/award (A): 62,100 (derivative) @ $0 · Grant/award (A): 20,700 (derivative) @ $0EDGAR
2022-01-314OLER ABRAHAM N. — SVP Corp Dev & Gen CounselPurchase (P): 1,500 @ $1.67EDGAR
2022-01-244OLER ABRAHAM N. — SVP Corp Dev & Gen CounselPurchase (P): 1,500 @ $2.02EDGAR
2022-01-184OLER ABRAHAM N. — SVP CORP DEV & GEN COUNSELPurchase (P): 1,500 @ $2.20EDGAR
2022-01-104OLER ABRAHAM N. — SVP Corp Dev & Gen CounselPurchase (P): 1,500 @ $2.39EDGAR
2021-11-234OLER ABRAHAM N. — SVP CORP DEV & GEN COUNSELPurchase (P): 1,000 @ $3.16EDGAR
2021-11-194OLER ABRAHAM N. — SVP Corp Dev & Gen CounselOption exercise/expiry (X): 5,000 @ $3 · Option exercise/expiry (X): 5,000 (derivative) @ $0EDGAR
2021-09-294OLER ABRAHAM N. — SVP Corp Dev & Gen CounselPurchase (P): 2,381 @ $4.20EDGAR
2021-09-294Gelder Mark S. MD — Chief Medical OfficerPurchase (P): 2,381 @ $4.20EDGAR
2021-09-284Fruchtman Steven M — President, Chief Executive Off, DirectorPurchase (P): 2,381 @ $4.20EDGAR
2021-09-284MARINO JAMES J — DirectorPurchase (P): 5,952 @ $4.20EDGAR
2021-08-044Fruchtman Steven M — President, Chief Executive Off, DirectorGrant/award (A): 113,000 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0EDGAR
2021-08-044Gelder Mark S. MD — Chief Medical OfficerGrant/award (A): 41,825 (derivative) @ $0 · Grant/award (A): 13,950 (derivative) @ $0EDGAR
2021-08-044Guerin Mark Patrick — Chief Financial OfficerGrant/award (A): 42,750 (derivative) @ $0 · Grant/award (A): 14,250 (derivative) @ $0EDGAR
2021-08-044OLER ABRAHAM N. — SVP Corp Dev & Gen CounselGrant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 13,400 (derivative) @ $0EDGAR

Recent 8-K events — Onconova Therapeutics, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-168-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-11-128-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-238-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-148-K2.02 — Results of Operations and Financial Condition
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-318-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-07-108-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-098-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.07 — Submission of Matters to a Vote of Security Holders
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-228-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-128-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-278-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR

Registration filings — Onconova Therapeutics, Inc.

Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ONTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs